Our results suggested that SPRC treatment could improve the myocardial function in diabetic mice with diabetic cardiomyopathy by attenuating myocardial hypertrophy, myocardial fibrosis, myocardial lipid accumulation, abnormalities in the ultrastructure of cardiomyocytes. The gene discussed is SPRR3; the disease is cardiac hypertrophy.